Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Plant Dis ; 107(4): 1172-1176, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-36222721

RESUMO

Citrus melanose, caused by the ascomycete fungus Diaporthe citri, is one of the most important diseases in China that affects not only the production but also the quality of citrus. In China, mancozeb is recommended to control melanose disease at the dose of 1.34 g/liter. However, it is widely applied in practice at the dose of 2.66 g/liter or even 4 g/liter, because reduced efficacy of the recommended dose was observed in regions severely damaged by melanose. In this study, some ecofriendly chemicals for melanose management were evaluated. First, the sensitivity to fungicides was screened in the laboratory based on the inhibition of mycelial growth and conidial germination of D. citri. Results showed that both quinone outside inhibitor (QoI) fungicides kresoxim-methyl and trifloxystrobin inhibited conidial germination of D. citri up to 100% at 0.1 µg/ml. The in vivo control efficacy on detached fruit indicated that treatments with elastic nanocopolymer film at 2 g/liter, mancozeb at 1 g/liter, and kresoxim-methyl at 0.1 g/liter significantly inhibited the infection process compared with the control treatment of mineral oil alone. In field trials, the efficacy of kresoxim-methyl at 0.1 g/liter and elastic nanocopolymer film at 2 g/liter mixed with mancozeb at 1 g/liter was equal to that of mancozeb at 2.66 g/liter. The use of mancozeb could be reduced greatly, and the newly developed fungicide combinations are more environmentally friendly due to the low toxicity of both QoI fungicides and elastic nanocopolymer film. The newly developed method with ecofriendly chemicals should play an important role in the management of citrus melanose in the future.


Assuntos
Citrus , Fungicidas Industriais , Maneb , Doenças das Plantas , Citrus/microbiologia , Fungicidas Industriais/farmacologia
2.
Plant Dis ; 102(8): 1612-1618, 2018 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-30673416

RESUMO

Resistance to succinate dehydrogenase inhibitors (SDHI) in Botrytis cinerea is associated with point mutations in the target gene succinate dehydrogenase subunit B (SdhB). The substitution from histidine to arginine at codon 272 (H272R) is currently the predominant mutation in SDHI-resistant populations in B. cinerea worldwide. In order to monitor the development of resistance to SDHI, a rapid, simple, and efficient method with high specificity to the H272R point mutation was developed based on loop-mediated isothermal amplification (LAMP). To specifically detect the H272R mutation, a set of four primers was designed based on the sequence of SdhB, and the LAMP reaction was optimized. When SYBR Green I was added after reaction, only samples with the H272R mutation showed the color change (from brown to fluorescent yellow), indicating that this set of primers could successfully discriminate the H272R genotype from other genotypes. Specificity and accuracy tests showed that this LAMP assay had high specificity and accuracy. Moreover, the LAMP method was further simplified with fungal mycelia and conidia as the amplification template which could be prepared within 5 min. Due to the low cost, simplicity, high efficiency, and specificity, the developed LAMP assay may contribute to the monitoring of resistance development to SDHI in B. cinerea, especially in field and high-throughput experiments.


Assuntos
Botrytis/genética , Farmacorresistência Fúngica/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Fungicidas Industriais/farmacologia , Técnicas de Amplificação de Ácido Nucleico/métodos , Sequência de Bases , Benzotiazóis , DNA Fúngico/química , DNA Fúngico/genética , Diaminas , Farmacorresistência Fúngica/genética , Proteínas Fúngicas/antagonistas & inibidores , Proteínas Fúngicas/genética , Mutação de Sentido Incorreto , Micélio/genética , Compostos Orgânicos/química , Quinolinas , Reprodutibilidade dos Testes , Homologia de Sequência do Ácido Nucleico , Esporos Fúngicos/genética , Succinato Desidrogenase/antagonistas & inibidores , Succinato Desidrogenase/genética
3.
Plant Dis ; 102(12): 2578-2585, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30299208

RESUMO

Botrytis cinerea, the causal agent of gray mold, can result in considerable preharvest and postharvest losses in many economically valuable plant species. Fungicides were widely used to minimize such losses, but fungicide resistances were detected frequently. In the present study, we collected 164 isolates from nectarine and cherry in China and tested the sensitivity to six fungicides. Among the tested isolates, 71 (43.3%) were resistant to azoxystrobin, 14 (8.5%) to cyprodinil, 7 (4.3%) to boscalid, 4 (2.4%) to carbendazim, 1 (0.6%) to iprodione, and no isolates were found to be resistant to fludioxonil. The EC50 value and resistance factor (RF) of resistant isolates were determined. Fitness analysis showed that there were no significant differences between sensitive and resistant isolates for osmotic stress and pathogenicity, while more conidia production was observed for some resistant isolates. Control efficacy of fungicides showed that the resistant isolates could not be controlled efficiently by using corresponding fungicides. The point mutation G143A was detected in the Cyt b gene of the isolates resistant to azoxystrobin, while the point mutation H272R of SdhB gene was confirmed in boscalid-resistant isolates, and mutations E198V/A of TUB2 gene and mutation I365S of BcOs1 occurred in carbendazim-resistant and iprodione-resistant isolates, respectively. These results indicate that the occurrence of fungicide resistance greatly threatens the management of gray mold on stone fruits nectarine and cherry.


Assuntos
Botrytis/efeitos dos fármacos , Farmacorresistência Fúngica , Fungicidas Industriais/farmacologia , Doenças das Plantas/microbiologia , Prunus/microbiologia , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/farmacologia , Benzimidazóis/farmacologia , Compostos de Bifenilo/farmacologia , Carbamatos/farmacologia , China , Dioxóis/farmacologia , Frutas/microbiologia , Hidantoínas/farmacologia , Niacinamida/análogos & derivados , Niacinamida/farmacologia , Doenças das Plantas/prevenção & controle , Pirimidinas/farmacologia , Pirróis/farmacologia , Esporos Fúngicos
4.
Sheng Wu Gong Cheng Xue Bao ; 17(2): 121-5, 2001 Mar.
Artigo em Zh | MEDLINE | ID: mdl-11411215

RESUMO

The imposition of environmental stress leads to increased production of reactive oxygen species (ROS) in plant cells, Which can damage proteins, membrane lipids, DNA and other cellular components. Plants have evolved enzymatic and no-enzymatic protection mechanisms that efficiently scavenge ROS. Enzymatic detoxication system includes superoxide dismutase (SOD), ascorbate peroxidase (APX), catalase (CAT) and glutathione peroxidase (GAX); no-enzymatic antioxidants include ascorbic acid, glutathione, mannitol and carotenoids, which occur in high concentrations in plants. The over-expression and accumulation strategies of these antioxidants in plants have been followed up to now, and have gained many transgenic plants showing increased stress tolerance.


Assuntos
Plantas/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Engenharia Genética , Estresse Oxidativo
5.
Somat Cell Mol Genet ; 24(6): 363-9, 1998 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10763415

RESUMO

Tc1/mariner transposons are widespread in the eukaryotes. In vitro transposition test indicated that the transposase is the only protein that is needed in transpositions. It was shown later that the reconstructed Tc1-like transposon, "sleeping beauty" in fish, and the Tc1 transposon in C. elegans jumps in human cells. This discovery indicates that the Tc1/mariner transposon may be engineered as a somatic gene therapy vector if coupled with an efficient gene delivery system. We introduced the Tc1 transposon from C. elegans into different mammalian cell lines and detected the transposition events, indicating that Tc1 transposon functions in different mammalian cells. Interestingly, a high inversion frequency of the transposon was also detected, suggesting that this type of transposon may add variations to host genome when it is horizontally transferred into a new species.


Assuntos
Caenorhabditis elegans/genética , Inversão Cromossômica , Elementos de DNA Transponíveis/genética , Animais , Linhagem Celular , Eletroporação , Humanos , Células K562 , Células KB , Camundongos , Mutagênese Insercional/genética , Especificidade de Órgãos/genética , Plasmídeos/genética , Reação em Cadeia da Polimerase , Transfecção , Transposases/genética , Transposases/metabolismo , Células Tumorais Cultivadas
6.
Blood Cells Mol Dis ; 27(2): 530-8, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11500064

RESUMO

An RNA/DNA chimeric oligonucleotide was found to be effective in the targeted correction of point mutations in Escherichia coli, plant, and mammalian genomes. This strategy, named chimeraplasty, has the potential for gene therapy of many genetic diseases caused by point mutations. beta-Thalassemia is a very common human genetic disease and in most cases it is caused by point mutations. To test whether the chimeraplasty can be used to correct the point mutations responsible for beta-thalassemia, we introduced one mutated beta-globin gene, betaE, into MEL cells and successfully corrected the point mutation of the betaE gene with the highest correction efficiency of 1.9%. Furthermore, a targeted -202 C-->G mutation of the Ggamma-globin gene, which is associated with the elevated Ggamma-globin gene expression in the adult stage, was introduced into HeLa and CMK cells by an RNA/DNA oligonucleotide. These results indicated that the chimeraplasty has potential for human beta-thalassemia gene therapy.


Assuntos
Hemoglobina Fetal/genética , Talassemia beta/genética , Animais , Linhagem Celular , Regulação da Expressão Gênica , Marcação de Genes , Terapia Genética , Humanos , Mutagênese , Oligonucleotídeos , Mutação Puntual , Talassemia beta/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA